![NCI-Funded Clinical Research In Jeopardy, ASCO Focuses on Value of NCTN Groups](https://cdn.cancerletter.com/media/2024/01/06033920/40-23-faderally-funded-research.jpg)
![NCI-Funded Clinical Research In Jeopardy, ASCO Focuses on Value of NCTN Groups](https://cdn.cancerletter.com/media/2024/01/06033920/40-23-faderally-funded-research.jpg)
Cover Story
CHICAGO—The consequences of diminishing federal support for cancer research can be measured in the abstracts presented at the 50th annual meeting of the American Society of Clinical Oncology that concluded earlier this week.
By Tessa Vellek
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Georgetown-MedStar: Patients with cancer can rely on our lawyers to fight legal issues that harm health